Generex Biotechnology receives approval from the Ministry of Health of the United Arab Emirates to sell Generex Oral-lyn ™ to prominent Diabetes Centre in the Middle East region
Imperial College London Diabetes Centre receives approval to sell to patients through the diabetes centre in Abu Dhabi, United Arab Emirates
WORCESTER, Mass., December 11, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that the Ministry of Health of the United Arab Emirates, Drugs Control Department has issued a non-objection letter to the Imperial College London Diabetes Centre to import Generex Oral-lyn, Generex’s proprietary oral insulin spray product, into Abu Dhabi. The Manager of the Drugs Control Department indicated that importation of Generex Oral-lyn can be done by via the issuance of a purchase order from the Imperial College London Diabetes Centre to a drug store or pharmacy licensed by the Ministry of Health of the United Arab Emirates.
The Imperial College London Diabetes Centre (www.icldc.ae) is a state-of-the-art specialized centre which is part of the government-supported Zayed Military Hospital. An estimated total of 5,000 patients are treated at the Imperial College London Diabetes Centre which is considered a leading diabetes resource in the region. Along with Generex’s Middle Eastern distributor, Leosons General Trading Company, a leading distributor of North American healthcare products in the region, a submission was prepared and filed with the Ministry of Health, UAE which resulted in the importation approval.
According to the International Diabetes Federation the UAE has the second highest rate of diabetes in the world affecting 20% of residents.
Abu Dhabi is the capital and second largest city of the UAE with a population of 2.3 million. It is also geographically the largest of the seven emirates.
“We are pleased with the progress made by our Leosons General Trading Company,” said Anna Gluskin, President & Chief Executive Officer of Generex. “This step is significant in that it allows the Company to introduce Generex Oral-lyn ™ into the Middle East via an established organization with a strong diabetes treatment program. We anticipate that this model will serve the purpose of demonstrating the product’s safety and efficacy to other health agencies within the Middle East.”
About Leosons
Leosons is a 25-year old private multinational operating company in the Middle East focusing on the pharmaceutical and healthcare industry. Leosons distributes 15 healthcare-related products which are considered category leaders.